[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    3 Comments for this article
    Another hazard of vaping
    Frederick Rivara, MD, MPH | University of Washington
    Vaping has changed the tobacco smoking landscape and now may do the same with cannabis. Vaping intensified the drug effects of cannabis in this small crossover study. Will the FDA which has become more aggressive in limiting vaping of tobacco also do so for cannabis. Will large states like California inaction restrictions?
    CONFLICT OF INTEREST: Editor in Chief, JAMA Network Open
    Have you seen what happened to this?
    Adam Gordon, BS | Euphoric Cannabis Marketing
    Have you seen what has happened to this paper in the cannabis press? Look at this: https://www.marijuanamoment.net/vaporized-marijuana-produces-a-stronger-high-than-smoking-it-study-finds/

    I am interested in tracking how we got from one to the other. Would you guys have any idea who initially picked this up?

    The story of this story is quite fascinating, I think.

    Thanks
    Adam
    CONFLICT OF INTEREST: None Reported
    Differential CNS effects of cannabis vs "medical" cannabis
    Gerald Pope, M.D. | W Beaumont Hospital
    Was the trial conducted with "medical" or commercial cannabis? Most of the effects observed appear to be related to central nervous system, cannabis induced, malfunctioning. Does "medical" cannabis differ in its physiological CNS effects? Does it produce therapeutic effects rather-than psychopathology-or is it a misnomer?
    CONFLICT OF INTEREST: None Reported
    Original Investigation
    Substance Use and Addiction
    November 30, 2018

    Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis: A Crossover Trial

    Author Affiliations
    • 1Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • 2RTI International, Research Triangle Park, North Carolina
    • 3Division of Workplace Programs, Substance Abuse and Mental Health Services Administration, Rockville, Maryland
    JAMA Netw Open. 2018;1(7):e184841. doi:10.1001/jamanetworkopen.2018.4841
    Key Points español 中文 (chinese)

    Question  How does smoked and vaporized cannabis acutely influence subjective drug effects, cognitive and psychomotor performance, and cardiovascular measures in healthy adults who infrequently use cannabis (>30 days since last use)?

    Findings  In a crossover trial of 17 healthy adults, inhalation of smoked and vaporized cannabis containing 10 mg of Δ9-tetrahydrocannabinol (THC) produced discriminative drug effects and modest impairment of cognitive functioning, while inhalation of a 25-mg dose of THC was associated with pronounced drug effects, increased incidence of adverse effects, and significant impairment of cognitive and psychomotor ability. Vaporized cannabis produced greater pharmacodynamic effects and higher concentrations of THC in blood compared with equal doses of smoked cannabis.

    Meaning  Significant, sometimes adverse, drug effects can occur at relatively low THC doses in infrequent cannabis users, and accordingly these data should be considered with regard to regulation of retail cannabis products and education for individuals initiating cannabis use.

    Abstract

    Importance  Vaporization is an increasingly popular method for cannabis administration, and policy changes have increased adult access to cannabis drastically. Controlled examinations of cannabis vaporization among adults with infrequent current cannabis use patterns (>30 days since last use) are needed.

    Objective  To evaluate the acute dose effects of smoked and vaporized cannabis using controlled administration methods.

    Design, Setting, and Participants  This within-participant, double-blind, crossover study was conducted from June 2016 to January 2017 at the Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, and included 17 healthy adults. Six smoked and vaporized outpatient experimental sessions (1-week washout between sessions) were completed in clusters (order counterbalanced across participants); dose order was randomized within each cluster.

    Interventions  Cannabis containing Δ9-tetrahydrocannabinol (THC) doses of 0 mg, 10 mg, and 25 mg was vaporized and smoked by each participant.

    Main Outcomes and Measures  Change from baseline scores for subjective drug effects, cognitive and psychomotor performance, vital signs, and blood THC concentration.

    Results  The sample included 17 healthy adults (mean [SD] age, 27.3 [5.7] years; 9 men and 8 women) with no cannabis use in the prior month (mean [SD] days since last cannabis use, 398 [437] days). Inhalation of cannabis containing 10 mg of THC produced discriminative drug effects (mean [SD] ratings on a 100-point visual analog scale, smoked: 46 [26]; vaporized: 69 [26]) and modest impairment of cognitive functioning. The 25-mg dose produced significant drug effects (mean [SD] ratings, smoked: 66 [29]; vaporized: 78 [24]), increased incidence of adverse effects, and pronounced impairment of cognitive and psychomotor ability (eg, significant decreased task performance compared with placebo in vaporized conditions). Vaporized cannabis resulted in qualitatively stronger drug effects for most pharmacodynamic outcomes and higher peak concentrations of THC in blood, compared with equal doses of smoked cannabis (25-mg dose: smoked, 10.2 ng/mL; vaporized, 14.4 ng/mL). Blood THC concentrations and heart rate peaked within 30 minutes after cannabis administration and returned to baseline within 3 to 4 hours. Several subjective drug effects and observed cognitive and psychomotor impairments persisted for up to 6 hours on average.

    Conclusions and Relevance  Vaporized and smoked cannabis produced dose-orderly drug effects, which were stronger when vaporized. These data can inform regulatory and clinical decisions surrounding the use of cannabis among adults with little or no prior cannabis exposure.

    Trial Registration  ClinicalTrials.gov Identifier: NCT03676166.

    ×